Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system
With the increased use of immune checkpoint inhibitors (ICIs) in advanced lung cancer, adverse events (AEs), particularly immune-related AEs (irAEs), have garnered considerable interest. We conducted a comprehensive assessment of the toxicity profile in advanced lung cancer using multi-source medica...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | anglais |
| Publié: |
2022
|
| Accès en ligne: | https://doi.org/10.1016/j.eclinm.2022.101535 http://www.thelancet.com/article/S2589537022002656/pdf |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|